HIND Stock Rallies 70% Pre-Market Today – Find Out Why
Synopsis
In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said.
Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrop has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied by over 60% in pre-market trading on Wednesday.
Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome.
In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company stated.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.